IN2012DN03177A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03177A
IN2012DN03177A IN3177DEN2012A IN2012DN03177A IN 2012DN03177 A IN2012DN03177 A IN 2012DN03177A IN 3177DEN2012 A IN3177DEN2012 A IN 3177DEN2012A IN 2012DN03177 A IN2012DN03177 A IN 2012DN03177A
Authority
IN
India
Prior art keywords
targeting molecule
conjugated
complex
antibody
moiety
Prior art date
Application number
Other languages
English (en)
Inventor
William J Mcbride
Souza Christopher A D
David M Goldenberg
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of IN2012DN03177A publication Critical patent/IN2012DN03177A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
IN3177DEN2012 2009-12-04 2010-12-02 IN2012DN03177A (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26677309P 2009-12-04 2009-12-04
US30228010P 2010-02-08 2010-02-08
US31612510P 2010-03-22 2010-03-22
US34748610P 2010-05-24 2010-05-24
US38172010P 2010-09-10 2010-09-10
US38826810P 2010-09-30 2010-09-30
PCT/US2010/058724 WO2011068965A1 (fr) 2009-12-04 2010-12-02 Procédés et compositions de marquage f-18 amélioré de protéines, peptides et autres molécules

Publications (1)

Publication Number Publication Date
IN2012DN03177A true IN2012DN03177A (fr) 2015-09-25

Family

ID=44115287

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3177DEN2012 IN2012DN03177A (fr) 2009-12-04 2010-12-02

Country Status (8)

Country Link
US (3) US8202509B2 (fr)
EP (1) EP2507254A4 (fr)
JP (1) JP5789821B2 (fr)
CN (1) CN102666567B (fr)
AU (1) AU2010326004B2 (fr)
CA (1) CA2782223A1 (fr)
IN (1) IN2012DN03177A (fr)
WO (1) WO2011068965A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563433B2 (en) * 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US20100226884A1 (en) * 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
US20160045626A1 (en) * 2007-01-11 2016-02-18 Immunomedics, Inc. Methods and Compositions for Improved Labeling of Targeting Peptides
US8545809B2 (en) * 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
US8398956B2 (en) * 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
US8889100B2 (en) * 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US8709382B2 (en) * 2007-01-11 2014-04-29 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
WO2010011367A2 (fr) * 2008-02-22 2010-01-28 Illinois Institute Of Technology Ligands bimodaux avec des fractions de liaison macrocycliques et acycliques, complexes et compositions les comprenant, et procédés d’utilisation
US10189803B2 (en) 2008-02-22 2019-01-29 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
US10556873B2 (en) 2008-02-22 2020-02-11 Illinois Institute Of Technology Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
IN2012DN03177A (fr) * 2009-12-04 2015-09-25 Immunomedics Inc
EP2651411B1 (fr) * 2010-12-13 2020-09-16 Immunomedics, Inc. Procédés et compositions permettant un marquage amélioré par le 18-f de protéines, de peptides et d'autres molécules
EP2717985A4 (fr) * 2011-06-09 2015-02-25 Ge Healthcare Ltd Dispositif et procédé de distillation
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
GB201201062D0 (en) * 2012-01-23 2012-03-07 Ge Healthcare Ltd Radiofluorination method
CN104363919A (zh) 2012-06-01 2015-02-18 Ibc药品公司 具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
CN102675329B (zh) * 2012-06-05 2014-12-24 浙江大学 一种正电子发射断层显像剂及其制备方法
US20150191543A1 (en) * 2012-08-06 2015-07-09 The Regents Of The University Of California Engineered antibody fragments for targeting and imaging cd8 expression in vivo
CN102911256B (zh) * 2012-11-02 2016-06-01 厦门大学 一种放射性标记的多肽配合物及其制备方法和应用
JP6391095B2 (ja) * 2012-11-30 2018-09-19 国立大学法人京都大学 ポリペプチド及びイメージング方法
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
CN103267850B (zh) * 2013-04-27 2015-04-15 深圳先进技术研究院 用于肿瘤病理诊断的探针及其制备方法和应用
GB201308053D0 (en) * 2013-05-03 2013-06-12 Ge Healthcare Ltd Metal complexes and fluorination thereof
WO2015051362A1 (fr) 2013-10-04 2015-04-09 Illinois Institute Of Technology Chélateurs multifonctionnels, complexes, et compositions de ceux-ci, et leurs procédés d'utilisation
EP3077407A4 (fr) * 2013-12-03 2017-07-19 Millennium Pharmaceuticals, Inc. Composés et compositions pour l'imagerie de cellules exprimant gcc
US20150217006A1 (en) * 2014-02-06 2015-08-06 Immunomedics, Inc. Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
US20160331852A1 (en) * 2015-05-11 2016-11-17 Memorial Sloan Kettering Cancer Center Radioligands for pretargeted pet imaging and methods of their therapeutic use
US20170007727A1 (en) * 2015-07-07 2017-01-12 Immunomedics, Inc. METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
TWI603980B (zh) * 2015-09-01 2017-11-01 免疫功坊股份有限公司 用以治療病理性血栓的聯合接合物構型藥物
WO2017070752A1 (fr) * 2015-10-29 2017-05-04 The University Of Queensland Agents d'imagerie
WO2018147960A1 (fr) 2017-02-08 2018-08-16 Imaginab, Inc. Séquences d'extension pour dianticorps
CN107312070A (zh) * 2017-05-03 2017-11-03 厦门大学附属第医院 一种18f标记的pet多肽探针及其制备方法
CN108314678B (zh) * 2018-01-17 2019-11-08 浙江大学 以磷脂酰丝氨酸为靶点的分子探针及其用途
US12103927B2 (en) 2018-03-30 2024-10-01 Centre National De La Recherche Scientifique Pyclen-based macrocyclic ligands, chelates thereof and uses thereof
WO2019227490A1 (fr) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions et procédés d'imagerie
CN112638415B (zh) * 2018-07-26 2024-07-02 大有华夏生物医药集团有限公司 用于成像的组合物和方法
MX2021008230A (es) * 2019-01-07 2021-08-11 Astellas Pharma Inc Conjugado que comprende ligando y fragmento fab de anticuerpo ceacam5.
CN113795511B (zh) * 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
US20220259160A1 (en) * 2019-08-21 2022-08-18 Nihon Medi-Physics Co., Ltd. Method for producing radioactive metal complex
EP4058423A1 (fr) * 2019-11-13 2022-09-21 Duke University Fractions prothétiques radiohalogènes et biomolécules radiomarquées
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CA3215787A1 (fr) * 2021-03-31 2022-10-06 Nihon Medi-Physics Co., Ltd. Complexe radioactif d'anticorps anti-egfr, et produit radiopharmaceutique
JP2024526275A (ja) * 2021-06-29 2024-07-17 ライフ モレキュラー イメージング リミティド 放射性金属標識キレート官能基化ターゲティングコンジュゲートの放射線医薬調製のための新規のキット
CN113773365A (zh) * 2021-09-09 2021-12-10 原子高科股份有限公司 生长抑素类似物及其应用
EP4273142A1 (fr) 2022-05-06 2023-11-08 Université de Bretagne Occidentale Chélates picolinate cyclam au palladium et leurs utilisations
WO2024238987A2 (fr) * 2023-05-18 2024-11-21 The Regents Of The University Of California Oligosaccharides marqués et procédés d'utilisation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5446147A (en) * 1992-04-03 1995-08-29 Trustees Of The University Of Pennsylvania Fluorinated and iodinated dopamine agents
DE69837095T2 (de) * 1997-09-03 2007-11-22 Immunomedics, Inc. Fluorierung von proteinen und peptiden für positronemissionstomographie
US6071490A (en) * 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7387772B1 (en) * 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7405320B2 (en) * 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US6056939A (en) * 1998-08-28 2000-05-02 Desreux; Jean F. Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals
DE19846148C2 (de) * 1998-10-01 2002-10-10 Igor Popov Verfahren zur Beurteilung der oxidativen Modifikation proteinhaltiger Stoffe mittels Messung ihrer antiradikalen Aktivität
US6207858B1 (en) * 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives
AU785505B2 (en) * 1999-10-15 2009-02-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
AU2001245401A1 (en) * 2000-03-01 2001-09-12 Sumitomo Pharmaceuticals Company, Limited Hydrazones and analogs as cholesterol lowering agents
AU6836301A (en) * 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
US7011816B2 (en) * 2001-12-26 2006-03-14 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67
US7081452B2 (en) * 2002-06-03 2006-07-25 The United States Of America As Represented By The Department Of Health And Human Services Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same
US7563433B2 (en) * 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US7993626B2 (en) * 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
JP4874090B2 (ja) * 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド 治療薬および診断薬を投与するための方法および組成物
EP1660519B1 (fr) * 2003-07-29 2014-05-14 Immunomedics, Inc. Conjugués comprenant le 2-[18F]-fluoro-2-désoxy-D-glucose et une molécule peptidique
WO2005077967A1 (fr) * 2004-02-13 2005-08-25 The University Of British Columbia Composes et compositions radiomarques, leurs precurseurs et leurs procedes de production
DE102004034517A1 (de) * 2004-07-16 2006-02-16 Covion Organic Semiconductors Gmbh Metallkomplexe
WO2006017619A2 (fr) * 2004-08-06 2006-02-16 The Regents Of The University Of California Peptides cycliques de liaison a un recepteur et leurs methodes d'utilisation
CA2604032C (fr) * 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methodes de generation de complexes lies stablement composes d'homodimeres, d'homotetrameres ou de dimeres de dimeres et utilisations associees
JP2009508090A (ja) * 2005-08-31 2009-02-26 イムノメディクス， インコーポレイテッド 予め標的化されたポジトロン放出断層撮影画像化のためのｆ−１８ペプチド
TWI303332B (en) * 2006-08-04 2008-11-21 Largan Precision Co Ltd Optical lens assembly
US7666392B2 (en) * 2006-09-15 2010-02-23 Siemens Medical Solutions Usa, Inc. Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
US8153100B2 (en) * 2007-01-11 2012-04-10 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
CN101568352B (zh) 2007-01-11 2013-08-21 免疫医学股份有限公司 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物
US8398956B2 (en) * 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
IN2012DN03177A (fr) * 2009-12-04 2015-09-25 Immunomedics Inc

Also Published As

Publication number Publication date
CA2782223A1 (fr) 2011-06-09
EP2507254A1 (fr) 2012-10-10
US20130211044A1 (en) 2013-08-15
CN102666567A (zh) 2012-09-12
US8444956B2 (en) 2013-05-21
US8617518B2 (en) 2013-12-31
EP2507254A4 (fr) 2013-12-04
AU2010326004B2 (en) 2016-04-21
US20120282178A1 (en) 2012-11-08
WO2011068965A1 (fr) 2011-06-09
US20110110854A1 (en) 2011-05-12
AU2010326004A1 (en) 2012-05-17
JP2013512918A (ja) 2013-04-18
US8202509B2 (en) 2012-06-19
CN102666567B (zh) 2015-08-26
JP5789821B2 (ja) 2015-10-07

Similar Documents

Publication Publication Date Title
EP2507254A4 (fr) Procédés et compositions de marquage f-18 amélioré de protéines, peptides et autres molécules
WO2012082618A3 (fr) Procédés et compositions permettant un marquage amélioré par le 18f de protéines, de peptides et d'autres molécules
EP2291678A4 (fr) Procédés et compositions améliorés pour le marquage au f-18 de protéines, peptides et autres molécules
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
GEP20196956B (en) Anti-gcc antibody molecules and related compositions and methods
EP2117604A4 (fr) Procédés et compositions pour un marquage par f-18 amélioré de protéines, peptides et autres molécules
MX340674B (es) Conjugados de anticuerpo de ingenieria de cisteina, radioetiquetados con circonio.
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
WO2011039510A3 (fr) Agents, utilisations et procédés
MX338754B (es) Anticuerpos humanos contra el factor tisular.
TN2009000063A1 (en) Compounds and methods for 18f labeled agents
MX357193B (es) Moleculas de union anti-alfa sinucleina.
MX2012006406A (es) Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
EP2244729A4 (fr) Anticorps obtenus par la cystéine pour conjugaison spécifique d'un site
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
NZ610239A (en) Cross-linkers and their uses
NZ712035A (en) Pyrrolobenzodiazepines and conjugates thereof
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EP2792236A3 (fr) Modèles animaux et molécules thérapeutiques
IN2012DN04908A (fr)
WO2015108998A8 (fr) Agents ciblant le cartilage et leur utilisation
CR11079A (es) Anticuerpos contra il-25
WO2012075361A3 (fr) Chimie click exempte de cuivre in vivo pour l'administration d'agents thérapeutiques et/ou diagnostiques
EA201290977A1 (ru) Гуманизированные антитела к il-25